EZH2 and melanoma: In addition, treatment with vemurafenib in combination with the EZH2 inhibitor GSK126 has been shown to result in improved inhibitory efficacy in vitro and in vivo compared with vemurafenib alone in BRAFi-susceptible melanoma [43].